Chimeric influenza vaccines

Patent metadata

Field	Value
Publication number	US-11918641-B2
Application number	US-202117998208-A
Country	US
Kind code	B2
Filing date	May 7, 2021
Priority date	May 8, 2020
Publication date	Mar 5, 2024
Grant date	Mar 5, 2024

Abstract

The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).

First claim

What is claimed is:

1. A chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA), wherein the chimeric influenza virus HA polypeptide comprises an amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 8, or SEQ ID NO: 12.

2. The polypeptide of claim 1 , wherein one or more glycosites on HA are monoglycosylated, wherein the monoglycosylated HA has only N-Acetylglucosamine (GlcNAc) on each glycosite.

3. The polypeptide of claim 1 , wherein the chimeric influenza virus HA polypeptide is used as an immunogen.

4. An immunogenic composition comprising the chimeric influenza virus HA polypeptide of claim 1 and an adjuvant.

5. The immunogenic composition of claim 4 , wherein the adjuvant is a glycolipid adjuvant.

6. A method of immunizing a subject against influenza virus or preventing an influenza virus disease comprising administering an effective amount of a chimeric influenza virus hemagglutinin (HA) polypeptide of claim 1 to the subject.

7. The method of claim 6 , wherein the method elicits CD4 + and CD8 + T-cell immune responses.

8. The method of claim 6 , wherein the method induces stem-specific antibodies, with higher antibody-dependent cellular cytotoxicity (ADCC), better neutralizing and stronger cross-protection activities against H1, H3, H5 and H7 strains and subtypes.

9. The method of claim 6 , wherein the method enhances the vaccine efficacy with more IFN-γ, IL-4 and CD8 + memory T cells produced.

10. A recombinant polynucleotide comprising a nucleic acid sequence encoding the polypeptide of claim 1 and optionally a nucleic acid sequence encoding a signal peptide.

11. The recombinant polynucleotide of claim 10 , wherein the signal peptide comprises a sequence of SEQ ID NO: 13 or SEQ ID NO: 14.

12. A vector comprising the recombinant polynucleotide of claim 11 .

13. A host cell comprising the vector of claim 12 .

14. A method of immunizing a subject against influenza virus or preventing an influenza virus disease comprising administering an effective amount of an immunogenic composition of claim 4 to the subject.

Assignees

• Academia Sinica

Inventors

• Wong Chi-Huey
• Liao Hsin-Yu
• Wang Shih-Chi
• Ko Yi-An
• Lin Kuo-I
• Ma Che
• Cheng Ting-Jen

Classifications

• A61K39/145 Primary

  Orthomyxoviridae, e.g. influenza virus · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title

• C07K14/005

  from viruses · CPC title

• A61K2039/575

  humoral response · CPC title

• A61K39/12 Primary

  Viral antigens · CPC title